WAVE Life Sciences
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
733 Concord Ave, Cambridge, Massachusett...Phone Number
(617) 949-2900Website
www.wavelifesciences.comRevenue
$71.8 MillionStock Symbol
WVEIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About WAVE Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.Explore more
WAVE Life Sciences Org Chart
MG
Senior Director, Regulatory Affairs
CS
Senior Director, Regulatory Affairs CMC
LL
Director, Legal
MK
Director, Regulatory Affairs
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is WAVE Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once WAVE Life Sciences has new funding data
Earning: See what the market has to say on WAVE Life Sciences recently announced quarterly report
Check out if WAVE Life Sciences is spiking on competitors!
WAVE Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at WAVE Life Sciences
Check if WAVE Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when WAVE Life Sciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if WAVE Life Sciences had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to WAVE Life Sciences
Compare insights from companies similar to WAVE Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
WAVE Life Sciences
$71.8M
201-500
Public
$451.3M
2012
LR
Linda RockettSenior Vice President, General Counsel
$2.2B
501-1,000
Public
$2.8B
1980
FQ
Farzana QuddusPrincipal Engineer & Chief Marketing Officer, Operation
Company Profile Activity
Activity Insights
WAVE Life Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
WAVE Life Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about WAVE Life Sciences.
WAVE Life Sciences financials insights
Gather financial insights about WAVE Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Multiple Rounds
$196M
2017
Stock Offering
$93.5M
2019
Stock Offering
$161.8M
WAVE Life Sciences Tech Stack
A closer look at the technologies used by WAVE Life Sciences
See more technologies
Most Recent Scoops
Project
WAVE Life Sciences has reported confidence in achieving the 5% body weight reduction regulatory threshold for its INHBE obesity program, noting that its Phase I data showed greater fat loss than bimagrumab which achieved the 5% threshold in its Phase IIa obesity study while maintaining comparable lean mass outcomes.
Medical Research, Pharmaceuticals
Project
WAVE Life Sciences is running a high BMI Phase IIa study in two parallel cohorts one with diabetes and one without capturing endpoints including body weight reduction, liver fat reduction via MRI PDFF, hemoglobin A1C, lipid changes, and visceral fat to lean mass ratio (VMR), with Phase I VMR data outperforming GLP-1 semaglutide in a direct comparison to the BELIEVE study.
Medical Research
Project
WAVE Life Sciences is evaluating visceral fat as a potential registrational endpoint for its obesity program, citing visceral fat as the principal driver of pathology in cardiometabolic disease and the visceral fat to lean mass ratio (VMR) as a well-established tool for quantifying cardiometabolic risk outcomes, with the study capturing endpoints across obesity, Type 2 diabetes, and lipid parameters.
Medical Research
Project
WAVE Life Sciences has reported that its DMD program is generating strong muscle exposures and dystrophin expression, with observed improvements in time-to-rise clinical measurements, and that no developments have altered the timeline or trajectory for its accelerated approval pathway.
Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
WAVE Life Sciences News & Media
Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?
Is WVE a good stock to buy? We came across a bullish thesis on Wave Life Sciences Ltd. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on WVE. Wave Life Sciences Ltd.’s share was trading at $5.70 as of June 8th. Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and […]Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wave Life Sciences Ltd. (WVE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 8:00 AM EDTCompany ParticipantsPaul Bolno -...Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in June.This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding WAVE Life Sciences
Sign Up For FreeTo access detailed company insights
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables t... Read More
